Vor Biopharma raises $42M series A round

PureTech Health plc (LSE:PRTC) affiliate Vor Biopharma Inc. (Boston, Mass.) raised $42 million in a series A round led by 5AM Ventures and RA Capital to support development of the company's engineered hematopoietic stem cells (HSCs) that could enable broader use of targeted cancer immunotherapies.

PureTech founded Vor with Siddhartha Mukherjee, associate professor of medicine at Columbia University. The biotech uses CRISPR-based gene editing technology to modify HSCs ex vivo to remove epitopes targeted by immunotherapies such as CAR T (see "Beyond B Cells")...